Figure 1From: Effects of bevacizumab plus irinotecan on response and survival in patients with recurrent malignant glioma: a systematic review and survival-gain analysis Observed median overall survival and percentage of 1-year overall survival for patients with malignant glioma in all published data. These data showed a median overall survival time of 13.7 ± 11.1 months and 1-year overall survival percentage of 18.9 ± 21.1% for malignant glioma patients.Back to article page